Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo‐controlled trial

@article{Abdelmalek2009BetaineFN,
  title={Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo‐controlled trial},
  author={Manal F. Abdelmalek and Schuyler O. Sanderson and Paul Angulo and Consuelo Soldevila‐Pico and Chen Liu and Joy A Peter and Jill C. Keach and Matt C. Cave and Theresa S. Chen and Craig J. McClain and Keith D. Lindor},
  journal={Hepatology},
  year={2009},
  volume={50}
}
Based on animal studies and pilot studies in humans, betaine, a methyl donor for the remethylation of homocysteine, may be a therapeutic agent for nonalcoholic steatohepatitis (NASH). We evaluated the safety and efficacy of betaine for patients with NASH and whether betaine positively modified factors postulated to be “second hits” and underlying mechanisms of NASH. We conducted a randomized placebo‐control study of 55 patients with biopsy‐proven NASH who received either oral betaine (20 g… 
High‐dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double‐blind, randomized, placebo‐controlled trial
TLDR
High‐dose UDCA failed to improve the overall histology in patients with NASH in comparison with placebo, and with the exception of γ‐glutamyl transferase, UDCA did not improve laboratory data.
Impact of Betaine on Hepatic Fibrosis and Homocysteine in Nonalcoholic Steatohepatitis - A Prospective, Cohort Study
TLDR
Betaine appears to improve liver function tests, homocysteine levels and histology in this cohort of NASH patients, and large randomized studies with long-term follow up are required to assess the effect of betaine for this growing epidemic.
Chromium picolinate balances the metabolic and clinical markers in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial
TLDR
It was showed that consuming 400 µg/day of CrPic for 12 weeks in patients with NAFLD causes a significant change in leptin, adiponectin, oxidative stress (expect glutathione peroxidase), and body weight, compared to baseline.
Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta‐analysis
  • M. Han, O. Altayar, +9 authors M. Noureddin
  • Medicine
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2019
TLDR
In a meta‐analysis of randomized controlled trials of NASH, patients given placebo have significant histologic, radiologic, and biochemical responses and the placebo response should be considered in designing trials of agents for treatment ofNASH.
Cholic acid for hepatic steatosis in patients with lipodystrophy: a randomized, controlled trial.
TLDR
CA was well tolerated but did not reduce hepatic TG content in patients with lipodystrophy, as previously shown in mice and serum TG in humans.
Effect of Dietary Betaine on Metabolic Syndrome Risk Factors in Asian
TLDR
Low-dose betaine supplementation to subjects with mild fatty liver disease is safe and well tolerated and betaine increased plasma HDL which may reflect the favorable effects of betaine on liver function-related metabolic metabolism in Asian population.
A meta‐analysis of randomized trials for the treatment of nonalcoholic fatty liver disease
TLDR
Well‐designed RCTs of adequate size and duration, with histological endpoints, are needed to assess long‐term safety and efficacy of proposed treatments on patient‐oriented clinical outcomes.
Pharmacological therapy of nonalcoholic steatohepatitis
  • M. Hojo, Sumio Watanabe
  • Medicine
    Hepatology research : the official journal of the Japan Society of Hepatology
  • 2011
TLDR
Treatments for NASH included lipase‐inhibiting agents, drugs that target components of metabolic syndrome, antioxidants, liver cytoprotectants, and suppressors of inflammatory cytokines, with particular emphasis on their efficacy for the improvement of hepatic fibrosis.
The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial
TLDR
Reduction in ferritin by phlebotomy does not improve liver enzymes, hepatic fat, or IR in subjects with NAFLD, and no differences in any endpoint were noted in patients with hyperferritinemia at baseline.
Pharmacologic Management of Non-Alcoholic Fatty Liver Disease
TLDR
Based on risk-benefit profiles, pentoxifylline seems to have the best treatment outcomes currently, with significant improvement in histology while having minimal tolerable side effects.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 27 REFERENCES
Impact of Betaine on Hepatic Fibrosis and Homocysteine in Nonalcoholic Steatohepatitis - A Prospective, Cohort Study
TLDR
Betaine appears to improve liver function tests, homocysteine levels and histology in this cohort of NASH patients, and large randomized studies with long-term follow up are required to assess the effect of betaine for this growing epidemic.
Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study
TLDR
Betaine is a safe and well tolerated drug that leads to a significant biochemical and histological improvement in patients with NASH and deserves further evaluation in a randomized, placebo-controlled trial.
Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study.
TLDR
The 8-week treatment with betaine glucuronate combined with diethanolamine glucuronates and nicotinamide ascorbate was found effective in non-alcoholic steatohepatitis, a disorder for which the hitherto pharmacological interventions were poorly and inconsistently effective.
Involvement of AMP-activated protein kinase in beneficial effects of betaine on high-sucrose diet-induced hepatic steatosis.
TLDR
These findings are the first to suggest that betaine might serve as a therapeutic tool to attenuate hepatic steatosis by targeting the hepatic AMPK system.
Treatment of nonalcoholic fatty liver disease
TLDR
Subjects should be advised to avoid alcohol, lose weight, and exercise regularly, and meticulous attention should be paid to the control of their risk factors such as diabetes and hyperlipidemia.
Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.
TLDR
Features suggestive of NASH are more frequently observed in HCC arising in patients with CC than in age- and sex-matched HCC patients of well-defined viral or alcoholic etiology.
Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease
  • M. Charlton, P. Kasparova, +5 authors K. Batts
  • Medicine
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2001
TLDR
The frequency of NASH as a cause of end‐stage liver disease was prospectively determined in patients evaluated for liver transplantation and posttransplantation histological characteristics in patients with NASH and compared with patients with pretransplantation diagnoses of cholestatic liver diseases, alcoholic disease, and hepatitis C.
Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity
TLDR
The prevalence of hepatic steatosis was greater in men than women among whites, but not in blacks or Hispanics, and significant ethnic and sex differences in the prevalence may have a profound impact on susceptibility to Steatosis‐related liver disease.
Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions
TLDR
There are no systems for grading necroinflammatory activity or for staging fibrosis as exist for various other forms of chronic liver disease and this study proposes a grading and staging system that reflects the unique histological features of nonalcoholic steatohepatitis.
...
1
2
3
...